Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
Holding ACRV?
Track your performance easily
ACRV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.19 - $11.90
Previous Close$8.23
Volume53.76K
Average Volume (3M)87.80K
Market Cap
$254.90M
Enterprise Value$78.58M
Total Cash (Recent Filing)$180.54M
Total Debt (Recent Filing)$4.22M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding30,972,163
10 Day Avg. Volume40,442
30 Day Avg. Volume87,795
Standard Deviation0.27
R-Squared0.00930
Alpha0.00424
Financial Highlights & Ratios
Price to Book (P/B)2.36
Price to Sales (P/S)1980.83
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit586.45
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$22.13Price Target Upside163.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Acrivon Therapeutics, Inc. News
PremiumCompany Announcements
Acrivon Therapeutics: Promising Trial Results and FDA Clearance
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPreclinical studies showcase the potential of ACR-2316 to be best in class, indicating strong promise for its future performance.
Competitive EfficacyACR-368 data continue to show promising efficacy in an ESMO endometrial update, with response rates well above SoC and other new and developmental-stage assets, including ADCs.
Strategic ValidationAnalysts believe positive results with ACR-2316 will fully validate Acrivon's approach and platform, reinforcing confidence in the company's strategy.
Bears Say
Clinical Trial ChallengesAprea presented initial first-in-human data of their WEE1 inhibitor, APR-1051, where 1 patient had disease progression and another dropped out before hitting the 2-month mark.
Drug EfficacyData from a peer's trial with a similar WEE1 inhibitor showed no objective responses, highlighting challenges in this drug class.
Response RatesThe BM- patient cohort in both endometrial and ovarian cancers are showing low response rates.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $3.19 and its highest was $11.90 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 133 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 30,972,162 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Among the largest hedge funds holding Acrivon Therapeutics, Inc.’s share is RA Capital Management. It holds Acrivon Therapeutics, Inc.’s shares valued at 48M.
---
Acrivon Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.13 (163.77% Upside)
$22.13 (163.77% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 5.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.11%
12-Months-Change
Fundamentals
Return on Equity
-37.78%
Trailing 12-Months
Asset Growth
44.07%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Month Forecast
Average Price Target
$22.13
▲(163.77% Upside)
Technical Analysis
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+10.47%
reiterated a buy rating 16 days ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +10.47% per trade.
---